tbuckley/cabot-search huggingface dataset:
SAT0472 Role of MRI in the Follow-up of Patients with Myositis
Authors: N. Pipitone, A. Notarnicola, L. Spaggiari, A. Scardapane, G. Levrini, F. Iannone, G. Lapadula, G. Zuccoli, C. Salvarani
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> MRI is widely used to evaluate muscle inflammation in myositis. Muscle edema on STIR sequences is thought to reflect active inflammation. However, it is unclear how useful MRI is in following up patients with myositis, in particular which is its sensitivity to change after treatment onset or intensification. <h3>Objectives</h3> To assess changes in MRI muscle edema and to correlate MRI edema score with serum creakine kinase (CK) and muscle strength in a cohort of patients with myositis at their first presentation to our centers (T0) and at follow-up after onset/intensification of immunosuppressive therapy (T1). <h3>Methods</h3> We enrolled in 2 Rheumatology centers 36 patients, 17 with dermatomyositis (DM) and 19 with polymyositis (PM) diagnosed according to Bohan and Peter criteria. In all patients, CK was measured, manual muscle test (MMT) was performed and MRI sequences were acquired within a week. MRI edema (1= present, 0= absent) was assessed bilaterally in 17 thigh and pelvic floor muscles. An MRI composite edema score (0-17) was calculated by adding the separate scores bilaterally and dividing them by two as described elsewhere (1). The CK upper limit of normal was 190 U/l. The (single measures) intraclass correlation coefficient (ICC) between the Radiologists involved was 0.78. Muscle strength was measured by MMT and graded according to the Medical Research Council extended scale (0-5). The ICC between the 2 physicians performing the MMT was 0.8. Analysis was performed by Wilcoxon sum rank and Spearman9s tests, as appropriate. <h3>Results</h3> Mean age (years ± SD) was 54±15. The ratio F:M was 31:5. MRI was positive (edema score ≥1) in 26 (72%) patients at T0 and in 18 (50%) at T1. Mean MRI edema score was 5±5.2 (mean ± SD) at T0 and 2.4±4.5 at T1 (p=0.002). Median and interquartile range (IQR) of MRI edema score were 3.5 (8) at T0 and 0.5 (4.5) at T1. CK was elevated in 22 (61%) patients at T0 and 10 (28%) at T1. CK was 1,816±3,560 at T0 and 531±1,536 at T1 (p=0.002). MMT score was 4.4±0.44 at T0 and 4.6±0.40 at T1 (p=0.02). MRI edema score did not correlate with CK or MMT scores neither at T0 nor T1. Eleven patients had a normal CK but a positive MRI at T0. In 5 of these patients, MRI became negative at T1. In the 11 patients with a normal CK but positive MRI at baseline, MRI edema score decreased from 6.7±5.3 at T0 to 2.4±2.7 at T1 (significance not calculated because of the small sample size). <h3>Conclusions</h3> MRI is a useful tool to monitor patients with myositis, and might particularly have a role in monitoring disease activity in patients with a normal serum CK at baseline. Larger studies are required to confirm our findings. The last 2 authors share senior authorship <h3>References</h3> Clin Exp Rheumatol 2012; 30:570-3 <h3>Disclosure of Interest</h3> None declared
Review of bulimia nervosa in males
Authors: D J Carlat, C A Camargo
Journal: American Journal of Psychiatry (1991)

The authors describe the distribution of bulimia nervosa among males and identify characteristics that distinguish male bulimics from their female counterparts.Potential references were identified through an English-language literature search using MEDLINE (1966 to April 1990) and through extensive manual searching of textbooks and reviews. All published works with original data or hypotheses concerning bulimia in males were included.Bulimia affects approximately 0.2% of adolescent boys and young adult men, and males account for 10%-15% of all bulimic subjects identified in community-based studies. Compared to their female counterparts, male bulimics appear to have a later age of onset; higher prevalences of premorbid obesity, homosexuality, and asexuality; and less concern with strict weight control. These findings are discussed from biological, psychological, and cultural perspectives to develop a fuller understanding of the pathogenesis of bulimia in males.Bulimia in males has received relatively little attention in the literature. Future research should focus on more rigorous analytic studies that include matched comparison groups of female bulimic and male nonbulimic subjects. Such studies would not only benefit male bulimics but might provide insight into the nature of bulimia in both sexes.
OP0179 Different Levels of Moderate Disease in Rheumatoid Arthritis (RA) are Associated with Varying Risk for Joint Destruction and Failure. Time to Update Das Cut-Offs for Biologic Dmard Use?: Table 1.
Authors: E. Nikiphorou, L. Carpenter, S. Norton, P. Kiely, J. Dixey, A. Young
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Sustained high disease activity in RA is known to result in worse outcomes. However, many patients remain in moderate disease activity states, yet their outcomes, are less well studied. <h3>Objectives</h3> To examine orthopaedic surgery as a surrogate marker of joint failure in patients who remain at different moderate disease activity levels in the first 5 years from disease-onset. <h3>Methods</h3> The Early RA Study (ERAS, n=1465, 1986-1999) and the Early RA Network (ERAN, n=1236, 2002-2012) collected standard clinical, radiological and laboratory measures yearly for a maximum (median) 25 (10) and 10 (3) years respectively. Clinical databases were validated with national sources: the National Joint Registry, Hospital Episode Statistics &amp; National Death Register. Treatment regimens followed guidelines of the era, mainly conventional DMARDs &amp; latterly biologics. Joint interventions were categorized into major (large joint replacements), intermediate (mainly synovectomies &amp; arthroplasties of wrist/hand, hind/forefoot) or minor (mainly soft tissue). Mean DAS28 was calculated for each patient from year1 (after treatment-onset) to 5 and categorized into either remission [RemDAS ≤2.6], low [LowDAS &gt;2.6 -3.2], low moderate [LowModDAS= &gt;3.2-4.19], high moderate [HighModDAS 4.2-5.1] or high DAS [HighDAS &gt;5.1]. <h3>Results</h3> A total of 2044 (76%) patients had at least two DAS28 recorded between year 1-5: 21% in RemDAS, 15% in LowDAS, 26% in LowModDAS, 21% in HighModDAS, 18% in HighDAS categories. The table shows that on moving from remission through to low/moderate/high states there was a progressive worsening in baseline clinical &amp; laboratory variables. In multivariate Cox regression models controlling for age at disease onset, gender, recruitment year, symptom duration, baseline rheumatoid factor, BMI, HAQ, erosions and Haemoglobin, HighModDAS (HR 1.80, 95%CI 1.05-3.11, p=0.034) and HighDAS (HR 2.59, 95%CI 1.49-4.52, p=0.001) predicted higher risk for intermediate surgery, unlike LowModDAS or LowDAS categories. In the case of major joint surgery, LowModDAS (HR 2.07, 95%CI 1.28-3.33), HighModDAS (HR 2.16, 95%CI 1.32-3.52) and HighDAS (HR 2.48, 95%CI 1.50-4.11) all predicted an increasing risk (p&lt;0.005). <h3>Conclusions</h3> Patients who remain in low or high moderate disease activity levels in the first 5 years of disease, despite conventional DMARD therapy, have similar risks for joint failure and surgery as those with persistently high DAS. This is highly relevant in health systems where restrictions exist in the use of biologic DMARDs, which are based on DAS cut-offs and exclude moderate RA. <h3>Disclosure of Interest</h3> None declared
Melamine contamination of dairy products in China – public health impact on citizens of the European Union
Authors: D Coulombier, C Heppner, S Fabiansson, A Tarantola, A Cochet, P Kreidl, R Reintjes
Journal: Eurosurveillance (2008)

On 10 September 2008, ProMED issued a request for information concerning 14 cases of kidney stones in infants hospitalised in Gansu province, China, in the previous two months [1]. On 21 September, Chinese authorities reported 39,965 cases of kidney stones in infants, including three deaths related to the consumption of melamine-contaminated powdered infant formula. On that day, 12,892 of them were hospitalised, 104 with severe illness. Most of these cases (82%) affected children under two years of age.
AB1056 Nailfold Capillaroscopy in Suspected Connective Tissue Disease Without Raynaud's Phenomenon: Table 1.
Authors: I. Cordeiro, A. Cordeiro, M.J. Santos, J. Canas da Silva
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The diagnostic<sup>1</sup> and prognostic<sup>2</sup> value of nailfold capillaroscopy (NCP) in patients with Raynaud9s phenomenon (RP) is well-established. However, its role in the assessment of patients without RP is still unclear. <h3>Objectives</h3> We aimed to assess the diagnostic role of NCP in suspected connective tissue disease (sCTD) without RP. <h3>Methods</h3> We included all patients with CTD or sCTD submitted to NCP assessment from January 2013 to December 2014. Clinical features were recorded, as well as the presence of antinuclear antibodies (ANA) and extractable nuclear antigens (ENA). NCP results were appraised according to capillary density, presence of dilatations, megacapillaries, hemorrhages, tortuosity, neovascularization and avascular areas. We classified NCP results as normal, nonspecific findings (NSF) and scleroderma pattern (SSP)<sup>3</sup>. Patients with sCTD were compared according to the presence/absence of RP, ANA/ENA and NCP findings. <h3>Results</h3> We included 112 patients: 95 (84.8%) female, with a mean age of 48±18 years. The most frequent CTDs were systemic sclerosis (SSc, n=33, 29.5%) and mixed CTD (n=6, 5.4%). Fifty-eight (51.8%) patients had sCTD – 37 (62.5%) had RP, 26 (55.3%) were ANA positive and 46 (86.8%) were ENA negative. Thirty-three (56.9%) had NSF; one sCTD patient exhibited SSP. Dilatations were present in 27 (51.9%), tortuosity in 40 (76.9%), hemorrhages in 22 (43.2%) and neovascularization in 8 (15.4%) individuals. Patients with and without RP were not different considering clinical features, ANA/ENA positivity and NCP findings (Table 1). The presence/absence of ANA and NCP findings were also not associated with distinct clinical features. <h3>Conclusions</h3> RP, ANA positivity and the presence of nonspecific findings in NCP were not discriminant in the short-term assessment of this patient group. Long term follow-up is needed in order to better understand the diagnostic and prognostic role of these NCP findings in both patients with and without RP. <h3>References</h3> Mannarino E, et al. Nailfold capillaroscopy in the screening and diagnosis of Raynaud9s phenomenon. Angiology 1994; 45: 37–42. Blockmans D, et al. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol 1996; 15: 148–53. Cutolo M, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000; 27: 155–60. <h3>Disclosure of Interest</h3> None declared
Addition of lithium carbonate to carbamazepine: hematological and thyroid effects
Authors: K G Kramlinger, R M Post
Journal: American Journal of Psychiatry (1990)

In view of the increasing use of lithium-carbamazepine combination therapy for refractory psychiatric disorders, the authors assessed the clinical laboratory effects of adding lithium to carbamazepine in 23 patients with affective disorders. Lithium produced a robust reversal of carbamazepine-induced leukopenia, increasing WBCs, predominantly neutrophils, to levels significantly above placebo baseline values. The combination produced additive antithyroidal effects, resulting in greater decreases in T4 and free T4 than with carbamazepine alone; the addition of lithium was associated with the emergence of a modestly higher TSH level. The authors discuss clinical and theoretical implications of these findings.
AB0944 Vitamin D Deficiency Might Contribute Fatigue and Disease Activity in Patients with Fibromyalgia:
Authors: D. Solmaz, O. Avci, B.C. Yalcin, S.P. Kara, M. Oran
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Fibromyalgia syndrome (FMS) is a chronic musculoskeletal system disease characterized by widespread pain and allodynia in at least 11/18 anatomic regions. Other important symptoms are fatigue, sleep disturbance and cognitive impairment. Widespread pain and fatigue can also be seen in patients with vitamin D deficiency. The association between low levels of 25-hydroxy (OH) vitamin D and non-specific musculoskeletal pain, including fibromyalgia syndrome, is controversial. <h3>Objectives</h3> The aim of this study is to assess fatigue and health quality in patients with isolated FMS, isolated vitamin D deficiency and FMS in together with vitamin D deficiency. <h3>Methods</h3> Patients followed by rheumatology clinic and classified as FMS according to ACR 2010 criteria were included in this study. 25- OH vitamin D levels below 20 ng/ml were accepted as vitamin D deficiency. Study groups classified as first group; patient with isolated FMS, second group; isolated vitamin D deficiency and third group was FMS in together with vitamin D deficiency. Patients with known calcium abnormality, hyperparathyroidism and osteomalacia were excluded. Fatigue level was measured by the visual analog scale (VAS) and functional assessments were determined by using BASFI and HAQ. Routine laboratory data were recorded. Widespread Pain Index (WPI); by evaluation of 0-19 tender points and Symptom Severity Score (SS); by the sum of fatigue, sleep, cognitive disturbances with general somatic symptoms were obtained. <h3>Results</h3> Patients distribution according to groups and properties were summarized in the table. As expected, in all groups, the majority of patients were female. While fatigue levels were similar between isolated vitamin D deficiency group and isolated FMS group, in FMS together with vitamin D deficiency group fatigue level was measured higher than the other two groups. Moderate and negative correlation was detected between fatigue level and vitamin D level (r:- 413, p:0,002). Negative relation was also detected between widespread pain index and symptom severity score with vitamin D level (r: -0.325, p: 0.023; r: -0.315, p: 0.037 respectively). HAQ and BASFI scores were higher with D vitamin deficiency between FMS patients (respectively p: 0.018, p&lt;0.001). <h3>Conclusions</h3> Vitamin D deficiency may contribute disease severity, fatigue and disturbances in health quality in FMS patients. Based on this, in FMS screening the level of vitamin D and correction may be helpful in symptom control. <h3>Disclosure of Interest</h3> None declared
MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (&gt; 65 Years of Age)
Authors: Katja Weisel, Jesús F. San Miguel, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, Anne Banos, Albert Oriol, Laurent Garderet, Michele Cavo, Valentina Ivanova, Adrian Alegre, Joaquin Martinez-Lopez, Christine I. Chen, Stefan Knop, Xin Yu, Latisha Watkins, Lars Sternas, Christian Jacques, Mohamed H. Zaki, Meletios A. Dimopoulos
Journal: Blood (2013)
Tamoxifen versus medroxyprogesterone acetate for metastatic breast cancer.
Authors: C D Atkins
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.11.2515 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7964968 Tamoxifen versus medroxyprogesterone acetate for metastatic breast cancer. C D AtkinsxC D AtkinsSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.11.2515 PDF "Tamoxifen versus medroxyprogesterone acetate for metastatic breast cancer.." Journal of Clinical Oncology, 12(11), pp. 2515–2516© 1994 by American Society of Clinical Oncology
Pathology of Infection with the JHM Virus&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: Alwin M. Pappenheimer, M.D.
Journal: JNCI Journal of the National Cancer Institute (1958)

Pathology of Infection with the JHM Virus Get access Alwin M. Pappenheimer, M.D. Alwin M. Pappenheimer, M.D. Department of Bacteriology and Immunology, Harvard Medical School, Boston, Massachusetts Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 5, May 1958, Pages 879–891, https://doi.org/10.1093/jnci/20.5.879 Published: 01 May 1958
Temporal Cessation of Sunitinib Treatment in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Study
Authors: Yuji Miura, Yoichi Fujii, Akihiko Shimomura, Naoki Sudo, Masaomi Ikeda, Koichi Suyama, Mitsuhiro Abe, Shuji Kameyama, Toshikazu Okaneya, Toshimi Takano
Journal: Annals of Oncology (2014)
AB0968 Adrenomedullin Levels in Patients with Familial Mediterranean Fever: A Long Term Follow-Up
Authors: A. Polat, C. Saglam, Y.G. Kurt, G. Basbozkurt, B. Sozeri, I. Dursun, O. Kasapcopur, H. Peru, D. Simsek, Z. Gunduz, E. Unsal, F. Gok, S. Ozen, E. Demirkaya
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Familial Mediterranean Fever (FMF) is the most common periodic fever syndrome, characterized by recurrent fever and serositis attacks. It has been shown that there might be an ongoing subclinical inflammation between attacks. Adrenomedullin (ADM) is synthesized in endothelium, and has been shown to have high levels in patients with inflammation such as FMF. Colchicine is the treatment of choice and given once or twice daily depending on expert opinion. <h3>Objectives</h3> In this study, it was aimed to investigate ADM as a marker for inflammation in pediatric patients with FMF who are using colchicine in different dosage schema <h3>Methods</h3> Pediatric patients with FMF diagnosed clinically and genetically confirmed were included in the study. The colchicine was started in one or two doses randomly. The clinical and laboratory parameters were assessed on six clinical visits made every two months. After the third visit the dosing schema was changed to twice or once depending on the schema at the beginning. <h3>Results</h3> A total of 37 patients (female/male ratio: 0.94) were included in the study. Mean age of patients, age at disease onset, and age at diagnosis were 7.78±2.00, 5.05±3.04, and 7.51±2.66 years, respectively. Twenty patients received colchicine in once daily dosage while 17 patients had in twice-daily dosage at the beginning of the study. There were 10 patients with heterozygote and 27 with homozygote MEFV mutations. After the treatment was started all patients demonstrated improvement in clinical and laboratory findings such as erythrocyte sedimentation rate and C-reactive protein. However, ADM levels did not show any correlation with ESR and CRP levels. Mean ADM levels in six consecutive visits were as follows, first 322.19±161.92 ng/L; second 330.50±189.63 ng/L; third 339.54±168.03 ng/L; forth 378.11±177.63 ng/L; fifth 328.91±172.30 ng/L and sixth 326.25±165.87 ng/L. ADM levels were similar in all visits (p=0.954) and did not show any difference between the first and second three visits i.e. before and after changing the dosage schema (p=0.593). <h3>Conclusions</h3> The results indicated that patients using colchicine in once or twice daily doses did not show any significant difference according to the clinical and laboratory findings and had similar effects in controlling disease manifestations. ADM levels did not demonstrate any alterations in all visits that may suggest the continuation of subclinical inflammation in these patients. <h3>Disclosure of Interest</h3> None declared
FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis: Table 1.
Authors: U. Kiltz, C. von Zabern, X. Baraliakos, F. Heldmann, B. Mintrop, I. Andreica, M. Sarholz, M. van Werde, C. Klink, D. Krause, F. Dybowski, L. Kalthoff, L. Hein, J. Braun
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In patients with tender and swollen finger joints, the differential diagnosis between rheumatoid arthritis (RA) and osteoarthritis (OA) of the hands can be initially difficult. In a previous pilot study we have shown that the positive response to a 3-day-course of 20 mg prednisolone (the "pred-test") differentiates between RA and OA of the hands. An subjective percentage of improvement of 40% was found to discriminate best. <h3>Objectives</h3> To study the diagnostic value of the pred-test in patients with possible RA. <h3>Methods</h3> Consecutive patients with hand pain referred because of suspected RA (n=100) were included in the study. Clinical examination by one experienced rheumatologist, laboratory tests, and magnetic resonance imaging (MRI) were regularly performed. All patients received 1g paracetamol/day for 5 days. On days 3-5 a morning dose of 20 mg of prednisolone was added. Hand pain was quantified on a numerical rating scale (NRS 0–10) and the subjective percentage of improvement recorded. The predefined cut-off of 40% improvement was applied to differentiate between responders and non-responders. Diagnoses were made by the expert who was unaware of the treatment result. Patients were reexamined at week 12 to confirm the diagnosis. <h3>Results</h3> There were 95 patients with complete data (Tab.1). RA was diagnosed in about half of the patients. RA patients had more swollen joints, higher CRP levels and a comparable HAQ (Tab.1). The pred test was positive in 42.1% of the patients (40/95). The median percentage of improvement after 3 days of 20 mg of prednisolone was higher in RA than in OA: 50% (IQR 30%&gt;60%) vs. 20% (IQR 10%&gt;30%), p&lt;0.001. The sensitivity and specificity of the pred-test was 65.9% (31/47) and 81.2% (39/48), and the positive and negative predictive value was 0.77 and 0.70, respectively. <h3>Conclusions</h3> This is the first evaluation of the widely used pred-test that has ever been performed. We found that this test has a moderate sensitivity and good specificity. We propose that rheumatologists use this test in uncertain clinical situations to be able to better differentiate between inflammatory arthritis and osteoarthritis. Finally, we hope that a negative test result will prevent patients to receive unnecessary glucocorticoid treatment, while a positive test will help to identify patients with inflammatory arthritis who can then receive proper treatment. <h3>Disclosure of Interest</h3> None declared